Get started
Aytu BioPharma, Inc.Aytu BioPharma, Inc.Aytu BioPharma, Inc.

Aytu BioPharma, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

AYTU chart


Full chart

AYTU upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪6.48 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.97 USD
Net income (FY)
‪−15.84 M‬ USD
Revenue (FY)
‪81.00 M‬ USD
Shares float
‪5.99 M‬
Beta (1Y)
0.85

Employees


Employees (FY)
102
Change (1Y)
−48 −32.00%
Revenue / Employee (1Y)
‪794.14 K‬ USD
Net income / Employee (1Y)
‪−155.33 K‬ USD

About Aytu BioPharma, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
John A. Donofrio
Website
aytubio.com
Headquarters
Englewood
Founded
2002
FIGI
BBG000VC2PT9
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

AYTU news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as AYTU.

Frequently Asked Questions


The current price of AYTU is 1.11 USD — it has increased by 5.71% in the past 24 hours. Watch Aytu BioPharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aytu BioPharma, Inc. stocks are traded under the ticker AYTU.
AYTU stock has risen by 12.12% compared to the previous week, the month change is a −11.20% fall, over the last year Aytu BioPharma, Inc. has showed a −60.22% decrease.
We've gathered analysts' opinions on Aytu BioPharma, Inc. future price: according to them, AYTU price has a max estimate of 8.00 USD and a min estimate of 8.00 USD. Watch AYTU chart and read a more detailed Aytu BioPharma, Inc. stock forecast: see what analysts think of Aytu BioPharma, Inc. and suggest that you do with its stocks.
AYTU reached its all-time high on Oct 22, 2008 with the price of 11,803,910.40 USD, and its all-time low was 0.95 USD and was reached on Apr 7, 2025. View more price dynamics on AYTU chart.
See other stocks reaching their highest and lowest prices.
AYTU stock is 5.71% volatile and has beta coefficient of 0.85. Track Aytu BioPharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Aytu BioPharma, Inc. there?
Today Aytu BioPharma, Inc. has the market capitalization of ‪6.85 M‬, it has decreased by −2.71% over the last week.
Yes, you can track Aytu BioPharma, Inc. financials in yearly and quarterly reports right on TradingView.
Aytu BioPharma, Inc. is going to release the next earnings report on May 19, 2025. Keep track of upcoming events with our Earnings Calendar.
AYTU earnings for the last quarter are −0.28 USD per share, whereas the estimation was −0.28 USD resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.17 USD per share. See more details about Aytu BioPharma, Inc. earnings.
Aytu BioPharma, Inc. revenue for the last quarter amounts to ‪16.22 M‬ USD, despite the estimated figure of ‪15.55 M‬ USD. In the next quarter, revenue is expected to reach ‪13.74 M‬ USD.
AYTU net income for the last quarter is ‪788.00 K‬ USD, while the quarter before that showed ‪1.47 M‬ USD of net income which accounts for −46.54% change. Track more Aytu BioPharma, Inc. financial stats to get the full picture.
No, AYTU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 27, 2025, the company has 102 employees. See our rating of the largest employees — is Aytu BioPharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Aytu BioPharma, Inc. EBITDA is ‪2.87 M‬ USD, and current EBITDA margin is 6.65%. See more stats in Aytu BioPharma, Inc. financial statements.
Like other stocks, AYTU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aytu BioPharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aytu BioPharma, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aytu BioPharma, Inc. stock shows the sell signal. See more of Aytu BioPharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.